Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.
To externally validate the updated 2012 Partin Tables in contemporary North American patients treated with radical prostatectomy (RP) for localized prostate cancer (PCa) at community institutions.



We examined records of 25,254 patients treated with RP and pelvic lymph node dissection (PLND) between 2010 and 2013, within the surveillance, epidemiology, and end results database. The ROC derived AUC assessed discriminant properties of the updated 2012 Partin Tables of organ confined disease (OC), extracapsular extension (ECE), seminal vesical invasion (SVI), and lymph node invasion (LNI). Calibration plots focused on calibration between predicted and observed rates.



Proportions of OC, ECE, SVI, and LNI at RP were 69.8%, 18.4%, 7.4%, and 4.4%, respectively. Accuracy for prediction of OC, ECE, SVI, and LNI was 70.4%, 59.9%, 72.9%, and 77.1%, respectively. In subgroup analyses in patients with nodal yield >10, accuracy for LNI prediction was 76.0%. Subgroup analyses in elderly patients and in African American patients revealed decreased accuracy for prediction of all four endpoints. Last but not least, SVI and LNI calibration plots showed excellent agreement, versus good agreement for OC (maximum underestimation of 10%) and poor agreement for ECE (maximum overestimation of 12%).



Taken together, the updated 2012 Partin Tables can be unequivocally endorsed for prediction of OC, SVI, and LNI in community-based patients with localized PCa. Conversely, ECE predictions failed to reach the minimum accuracy requirements of 70%. Prostate 77:105-113, 2017. © 2016 Wiley Periodicals, Inc.
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.|Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
Sami-Ramzi
SR
Leyh-Bannurah
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.|Department of Urology, University of Montreal Health Center, Montreal, Canada.
Stéphanie
S
Gazdovich
Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
Lars
L
Budäus
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.|Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Emanuele
E
Zaffuto
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.|Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Paolo
P
Dell'Oglio
Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alberto
A
Briganti
Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Firas
F
Abdollah
Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco
F
Montorsi
Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany.
Jonas
J
Schiffmann
Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation (VCORE), Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan.
Mani
M
Menon
Department of Urology Medical University of Vienna, Vienna, Austria.
Shahrokh F
SF
Shariat
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Margit
M
Fisch
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Felix
F
Chun
Department of Urology, University of Montreal Health Center, Montreal, Canada.
Markus
M
Graefen
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.|Department of Urology, University of Montreal Health Center, Montreal, Canada.
Pierre I
PI
Karakiewicz
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008197:Lymph Node Excision / Q000639:trends; D008297:Male; D008875:Middle Aged; D049451:Nomograms; D009656:North America / Q000453:epidemiology; D011159:Population Surveillance / Q000379:methods; D011468:Prostatectomy / Q000639:trends; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000601:surgery*; D018426:SEER Program / Q000592:standards*; D014481:United States / Q000453:epidemiology
North American; SEER; calibration; prediction tool; risk calculation; upstaging